Swedish Medtech start-up Capitainer raises SEK15 million to commercialise Capitainer qDBS dried blood spot sampling system

Stockholm, March 11, 2020: The Swedish Medtech start-up, Capitainer, today announced that it has closed a share issue of SEK15 million to commercialise its new dried blood spot sampling solution, Capitainer qDBS. Lead investors are Nordic Consumer Health and the US-based Wolf Family Trust, joined by a consortium of Nordic angel investors and Capitainer management.

The Capitainer qDBS solution is designed to enable convenient and quantitative blood sampling at the fingertip. The patented solution ensures an exact sample volume of 10µl blood to be collected. Patients simply place a blood drop on the qDBS card which automatically fills a microchannel with the required amount and discards any excess. The potential for human error is thus completely eliminated. Subsequently, the blood volume contained in the microchannel automatically transfers to a pre-punched DBS paper, forming an accurate and high-quality dried blood spot sample, preserved for quantitative analysis. The filled card can then be safely transported to the laboratory for analysis without the need for refrigeration or specialised packaging. Capitainer blood sampling therefore delivers cost savings, improved healthcare efficiency and patient experience, as well as reducing environmental impact.

“The dried blood spot collection card market size is currently expected to reach USD 337.3 million by 2026, expanding at a CAGR of 3.5%. However, with our next generation device, Capitainer qDBS with quantitative and easy to use sampling, we will not only expand the existing market, but also be able to enter the clinical home sampling market which we believe is a billion dollar USD market. We aim at making Capitainer products the new gold standard for home sampling of blood. As a founding investor, we are delighted to lead this round and look forward to a successful commercialisation,” says Mats Bergryd, CEO of Nordic Consumer Health.

“From wellness screening to serological diagnostics of infectious- and autoimmune diseases, the potential for Capitainer qDBS to further increase its already positive impact on healthcare provision and outcomes is enormous and we are delighted to invest in this round,” adds Bob Wolf, Founder and President of Specialty Diagnostix.

Christopher Aulin, CEO of Capitainer comments: “Over the last 12 months, we have seen a growing interest in Capitainer qDBS for both existing and new applications such as therapeutic drug monitoring, genomics and screening applications. With the fast growing demands for home sampling, we strongly believe that capillary blood will increasingly be seen as a viable and preferable alternative to venous blood. I would like to thank our investors, both new and existing, for their confidence and this funding will now enable us to accelerate our commercialisation activities for Capitainer qDBS.”

For more information, visit www.capitainer.se

Contact
Christopher Aulin, CEO t: +46 708 977 577
e: aulin@capitainer.se

Notes
Capitainer AB is a Swedish Medtech company founded in 2013 by Professor Olof Beck from the Department of Clinical Pharmacology at the Karolinska Institute and Professors Göran Stemme, Asso. Prof. Niclas Roxhed and PhD Gabriel Lenk from the division of Micro- and Nanosystems at the Royal Institute of Technology (KTH), Sweden and Peter Bräutigam, a business consultant.

Capitainer is a supplier of intelligent solutions for Dried Blood and Plasma Spot sampling serving several market segments, including but not limited, to Therapeutic Drug Monitoring, Drug Development and Drugs of Abuse and Alcohol testing. By using a combination of paper- and polymer microfluidics the precision and accuracy of metering of capillary blood is on par with that of a standard displacement pipette. Thus, the technology enables more convenient solutions for healthcare sampling and patients’ home sampling ensuring more reliable test results for healthcare and other providers of tests based on blood or plasma.

Read more news

Swedish medtech start-up Capitainer hires VWR veteran Tom Sölch as COO amid mounting interest in novel qDBS dried blood spot sampling system for COVID-19 testing and other key applications

    Stockholm, September 1, 2020: Swedish medtech start-up Capitainer hires VWR veteran Tom Sölch as COO amid mounting interest in novel qDBS dried blood spot sampling system for COVID-19 testing and other key applications Swedish medtech start-up Capitainer...

Meet us at IATDMCT Congress in Brisbane 16-19/9

    Capitainer participates in (IATDMCT) Congress 2018, 16–19 September 2018 in Brisbane, Australia The 16th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology (IATDMCT 2018) will be held from Sunday 16th to Wednesday 19th...

Meet us at AACC Annual Scientific Meeting

    Capitainer participates in AACC Annual Scientific Meeting July29-August 2, 2018 The 70th AACC Annual Scientific Meeting & Clinical Lab Expo is the largest global scientific conference and tradeshow in the field of laboratory medicine. This is part of...

Capitainer invited speaker at PRINSE’18

    Capitainer was invited speaker in the diagnostics session at PRINSE’18 (the 5th Printed Intelligense Industry Seminar) this year focusing on ”Manufacturing Solutions for Customer Needs and Vision to the Future”, Jan 31- Feb 1, 2018, in Oulu, Finland. The...

Ernst Westman new Chairman of the Board

    The board of directors has elected Mr. Ernst Westman as new Chairman of the Board of Capitainer AB. Mr. Westman has been President and CEO of the listed blood diagnostics Boule Diagnostics AB (publ) between 1994 to 2017 and now takes over the leadership in...

Ta blodprovet själv, KTH magazine

Hjärtpatienten Sigvard sitter hemma i köket och förbereder ett blodprov på sig själv. Efter hjärtattacken för ett halvår sedan behandlas han med den blodförtunnande medicinen Waran för att minska risken för återfall. Ett problem med Waran är att doseringen är väldigt...

Capitainer Featured on KTH Home Page

Capitainer technology is highlighted as a news article on KTH’s first page. Read more news Get In Touch   We are currently seeking funding to reach set-up milestones. We welcome investors interested to contact our CEO – Peter Brautigam for further...

Capitainer Selected Best Start-Up

Capitainer was selected best Start-Up at the Nordic Pitch Night event Aug 25 in Silicon Valley, USA Read more news Get In Touch   We are currently seeking funding to reach set-up milestones. We welcome investors interested to contact our CEO – Peter Brautigam for...

Nordic Life Science Days, Sept. 14-15 in Stockholm

Capitainer has been selected to exhibiting at the Nordic Life Science days Sept. 14-15 in Stockholm. Read more news Get In Touch   We are currently seeking funding to reach set-up milestones. We welcome investors interested to contact our CEO – Peter Brautigam...

AACC Annual Scientific Meeting & Clinical Lab Expo

Capitainer is presenting their technology at the 68th AACC Annual Scientific Meeting & Clinical Lab Expo Aug 1-4, in Philadelphia, USA. Read more news Get In Touch   We are currently seeking funding to reach set-up milestones. We welcome investors interested...

Brighter Startup Program

Capitainer is attending the Brighter Startup Program, a one week program for Swedish entrepreneurs located in Silicon Valley’s unique and leading innovation and entrepreneurship ecosystem. Read more news Get In Touch   We are currently seeking funding to reach...

Capitainer Exhibits at STING-day

Capitainer is selected as one of few KTH-start-ups to exhibit at the prestigious STING-day on May 28, an investor event gathering Stockholm’s most promising tech start-ups connecting then to VC’s and investors from around the world. Read more news Get In Touch  ...

Clinical Chemistry Meeting in Malmö

Capitainer is presenting at the Swedish Clinical Chemistry spring meeting in Malmö May 11-13, Sweden. Read more news Get In Touch   We are currently seeking funding to reach set-up milestones. We welcome investors interested to contact our CEO – Peter Brautigam...

KTH’s President’s innovation event

Capitainer is selected to present during KTH’s President’s innovation event. Read more news Get In Touch   We are currently seeking funding to reach set-up milestones. We welcome investors interested to contact our CEO – Peter Brautigam for further...

Capitainer Awarded 2 MSEK

Capitainer is awarded 2 MSEK in seed funding from the Swedish Innovation Agency VINNOVA in the competitive ViNNVerifiering program, a program in designed to promote the best academic start-up cases. Read more news Get In Touch   We are currently seeking funding...